Related Experiment Video
Updated: Feb 3, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
Published on: April 28, 2016
Mo-CBP3-PepI, Mo-CBP3-PepII, and Mo-CBP3-PepIII are synthetic antimicrobial peptides active against human pathogens
Jose T A Oliveira1, Pedro F N Souza2, Ilka M Vasconcelos1
1Department of Biochemistry and Molecular Biology, Federal University of Ceara, Fortaleza, Ceara, 60451, Brazil.
Abstract:
The efficiency of current antimicrobial drugs is noticeably decreasing and thus the development of new treatments is necessary. Natural and synthetic antimicrobial peptides (AMPs) have attracted great attention as promising candidates. Inspired on Mo-CBP3, an antimicrobial protein from Moringa oleifera seeds, we designed and synthesized three AMPs named Mo-CBP3-PepI, Mo-CBP3-PepII, and Mo-CBP3-PepIII. All these three peptides inhibited the growth of Candida species and pathogenic bacteria, penetrate into microbial cells, but none is hemolytic or toxic to human cells. Mo-CBP3-PepIII, particularly, showed the strongest antimicrobial activity against Staphylococcus aureus and Candida species, important human pathogens. Additionally, Mo-CBP3-PepIII did not exhibit hemolytic or toxic activity to mammalian cells, but increased Staphylococcus aureus plasma membrane permeabilization. In Candida parapsilosis, Mo-CBP3-PepIII induced pore formation in the plasma membrane and overproduction of reactive oxygen species. Bioinformatics analysis suggested that Mo-CBP3-PepIII is resistant to pepsin digestion and other proteolytic enzymes present in the intestinal environment, which opens the possibility of oral delivery in future treatments. Together, these results suggest that Mo-CBP3-PepIII has great potential as an antimicrobial agent against the bacterium S. aureus and the fungi C. parapsilosis.
Insights
New antimicrobial peptides (AMPs) were synthesized, inspired by a Moringa oleifera protein. Mo-CBP3-PepIII shows potent activity against Staphylococcus aureus and Candida species without harming human cells, suggesting potential for new treatments.
Area of Science:
- Microbiology
- Biochemistry
- Drug Discovery
Background:
- Declining efficacy of current antimicrobial drugs necessitates novel therapeutic agents.
- Antimicrobial peptides (AMPs) are emerging as promising candidates due to their broad-spectrum activity.
- Mo-CBP3, an antimicrobial protein from Moringa oleifera seeds, serves as inspiration for new peptide designs.
Purpose of the Study:
- To design and synthesize novel antimicrobial peptides (AMPs) inspired by Mo-CBP3.
- To evaluate the antimicrobial activity, cell penetration, and toxicity of the synthesized peptides.
- To investigate the mechanism of action of the most potent peptide against key human pathogens.
Main Methods:
- Design and synthesis of three AMPs: Mo-CBP3-PepI, Mo-CBP3-PepII, and Mo-CBP3-PepIII.
- Antimicrobial susceptibility testing against Candida species and pathogenic bacteria.
- Hemolysis and cytotoxicity assays using human cells.
- Confocal microscopy for cell penetration studies.
- Membrane permeabilization and reactive oxygen species (ROS) assays.
- Bioinformatics analysis for enzyme resistance prediction.
Main Results:
- All synthesized peptides inhibited microbial growth and penetrated microbial cells without exhibiting hemolytic or toxic effects on human cells.
- Mo-CBP3-PepIII demonstrated the strongest antimicrobial activity against Staphylococcus aureus and Candida species.
- Mo-CBP3-PepIII increased plasma membrane permeabilization in S. aureus and induced pore formation and ROS overproduction in Candida parapsilosis.
- Bioinformatics analysis indicated Mo-CBP3-PepIII resistance to gastrointestinal proteolytic enzymes.
Conclusions:
- Mo-CBP3-PepIII is a potent antimicrobial agent with a promising safety profile against human cells.
- The peptide's mechanism involves disruption of microbial cell membranes and ROS induction.
- Mo-CBP3-PepIII's resistance to enzymatic degradation suggests potential for oral administration, offering a novel therapeutic strategy.
Related Concept Videos
Enlargement of the Plasma Membrane
Plasma Membrane in Bacteria and Archaea
Fusion of Secretory Vesicles with the Plasma Membrane
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
Peptide Bonds
The Resting Membrane Potential
Antimicrobial Effectiveness

